share_log

Goldman Sachs Maintains Buy on Blueprint Medicines, Raises Price Target to $168

Goldman Sachs Maintains Buy on Blueprint Medicines, Raises Price Target to $168

高盛维持对蓝图药品的买入,将目标股价上调至168美元
Benzinga ·  05/06 11:17

Goldman Sachs analyst Terence Flynn maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $121 to $168.

高盛分析师特伦斯·弗林维持蓝图药业(纳斯达克股票代码:BPMC)的买入并将目标股价从121美元上调至168美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发